Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecfidera fatigue evaluation in relapsing-remitting multiple sclerosis
2013-001025-53Phase 4Terminated
- Sponsor
- Biogen
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Primary endpoint: Mean change from baseline in MS-related fatigue at 12 months. Started Mar 2014; status: terminated.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2013-001025-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001025-53.